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Summary Oestrogen receptor protein (ER) was detected in 9 of 11 samples of malignant breast tissue and 8
of 9 samples of normal breast tissue. Levels of cytosolic ER (ERJ) in malignant breast were 21-1102fmol mg-
soluble protein (Kd1.8x 10-9-3.1 x 10-8moll-1) and those of nucleosolic ER (ERj), 13-526fmolmg-'
soluble protein (Kd2.1 x 10-9-1.4 x 10 8mol '-1). In normal breast tissue ERC levels were 33-640fmolmg-
soluble protein (Kd 1.3 x 10-L-3.2 x 0- mol -'), ER. was detected in only 2 samples, 8 and 87fmol mg'
soluble protein with Kd3.2 x 10-9 and 1.4 x 10-91mol -' respectively. 17a-ethinyl-13,-ethyl-17,-hydroxy-4,15-
gonadiene-3-one (gestodene), a new synthetic progestogen displaced 3H-oestradiol (3H-E2) from both ERc
and ERn in malignant tissue but not in normal breast, or these receptors from endometrial tissue. In
competition studies gestodehe was 3 times more effective in displacing 3H-E2 from ERC and ERn in
malignant breast tissue than the natural ligand. Quantitation of ER by gestodene were ERr, 12-1134fmol
gestodene bound mg- soluble protein (Kd 1 x 10-9-8.1 x 10-9moll-1); ER., 17-531 fmol gestodene bound
mg
' soluble protein (Kd 1.6 x O1-9.1 x 10 8moll-'). L-13-ethyl-17a-ethinyl, 17,B-hydroxy-gonen-3-one
(levonorgestrel) showed no binding to ER in malignant breast, normal breast or endometrial tissue. In
circulation both gestodene and levonorgestrel displaced E2 from sex hormone binding globulin more than any
of the androgens tested. These results suggest that gestodene is a progestogen with oestrogenic and/or
antioestrogenic properties and provide strong evidence for differences in ER from malignant and normal
breast tissue.
Oestrogen receptor (ER) in human carcinoma of
the breast is the most widely studied steroid
receptor. ER has been extensively purified and
characterised (Jensen et al., 1982) and perhaps
together with the glucocorticoid receptor more is
known about its physicochemical forms and
characteristics than any other receptor (McGuire et
al., 1978; Grody et al., 1982). However, many
points of contention still remain (King & Green,
1984; Welshons et al., 1984; Szego & Pietra, 1985).
Recently, Jasper et al. (1985) reported different
physicochemical forms of ER in rat uterus and
pituitary gland based on the hypothesis of a
monomer-dimer relationship, and Brown et al.
(1984) found that the E2 dependent pS2 gene was
expressed in the MCF-7 cell line and malignant
breast samples but not in normal breast or ER
negative cell lines. Similarly, there have been many
reports on multiple receptor forms in tissues from
animals of different ages and endocrine status
(Jasper et al., 1985), on the sedimentation
behaviour of molybdate stabilised, non-activated
ER, on ER bound to E2 or to antioestrogens and
salt or heat-activated receptor (Katzenellenbogen et
al., 1978, 1981; McGuire et al., 1978; Grody et al.,
1982 and Keen et al., 1984). To date, however, in
no organ in any species have differences in binding
of a particular steroid metabolite or analogue by
ER been reported in a malignant tissue as
compared to the normal tissue of the same organ.
Here we report the significant binding of a
synthetic progestogen to ER in human malignant
breast tissue and its total lack of binding to ER in
normal breast tissue or to ER in endometrium. This
is all the more surpising because the 'down
regulation' of ER by progestogens has been
reported (Katzenellenbogen, 1980) but the binding
of this class of hormones to ER has not. As this
new progestogen may form part of an oral
contraceptive preparation, its binding in circulation
and to specific proteins in tissues requires
investigation and is reported here.
Materials and methods
3H-gestodene(specificactivity2.15 TBqmmol-1),3H-
levonorgestrel (specific activity 1.44TBqmmol -1)
and the corresponding radioinert compounds were
a gift from Schering Chemicals (UK) Ltd. 3H-
oestra-1,3,5(10)-triene-3,17fl-diol (Oestradiol, E2)
(specific activity 3.85 TBqmmol-1, 3H-Sa-androstan-
17f,-ol-3-one (Sc-dihydrotestosterone, DHT) (specific
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activity 5.30TBqmmol-1), 3H-17,B-hydroxyan-
drost-4-en-3-one (testosterone) (specific activity
3.89TBqmmol 1), 3H-5a-androstan-3a(3,B)-diols
(specific activities 1.52TBqmmol-1 each), 3H-
1 #,17,21-trihydroxy pregn-4-ene-3,20-dione (corti-
sol) (specific activity 3.0TBqmmol-1) and 3H-
pregn-4-ene-3,20-dione (progesterone) (specific
activity 3.66TBqmmol-') were purchased from
Amersham International, UK. Radioinert steroids
were obtained from Sigma Chemical Co. UK. In all
instances the purity of the steroids used was greater
than 99.9% as determined by thin layer
chromatography before use. Sephadex G-25,
Sephadex LH-20 and Sepharose 6B were obtained
from Pharmacia (GB) Ltd. Cibacron Blue 3GA-
Sepharose 6B was prepared as described by Heyns
and De Moor (1974). Radioactivity was determined
in a Packard Tri-Carb liquid scintillation counter
with an efficiency of 40% using 'Optiphase Safe'
(LKB/Fisons) as scintillant. Data were analysed by
Scatchard plots (Scatchard, 1949), with resolution of
curvilinear plots by the method of Chamness and
McGuire (1975).
Breast tissue was obtained at operation;
malignant breast samples were confirmed
histologically and normal breast samples were
obtained either from surrounding tissue (samples 1-
6, Table I) which was histologically confirmed as
normal or from operative breast reduction (samples
7-9, Table II) and were stored in liquid nitrogen
until assayed.
Estimation ofER
Cytosol and nucleosol fractions were prepared as
previously described (Greenway et al., 1981; Iqbal et
al., 1983) and the original tissue weight:volume
buffer was 1:20 in the incubates. Tissue samples
were manipulated below 4°C and were homogenised
in TED buffer (10mMTris, 1.5mMEDTA and
1.5mM dithiothreitol, pH 7.4) using an Ultra-Turrax
homogeniser before centrifugAtion at 160,000g for
1h, the resulting supernatant was used as cytosol.
The remaining pellet was washed with TES buffer
(10mmTris, 1 mmEDTA and 250mm sucrose,
pH7.4), centrifuged at 800g for 10min and the
supernatant discarded. The pellet was then
homogenised in TSMK buffer (10mmTris, 250mM
sucrose, 5mM MgCl2 and 25mmKCI, pH7.5),
centrifuged at 800g for 10min and the supernatant
discarded. The pellet was washed twice with TSMK
bufffer and finally suspended in TKED buffer
(TED buffer containing 0.5MKCl). The suspension
was kept at 4°C for 1 h to extract nuclear receptor
and then centrifuged at 15,000g for 30min, the
supernatant being retained as nucleosol.
ER was measured using the two-tier column
microassay employing Cibacron Blue 3GA-
Sepharose 6B for the affinity immobilisation of the
receptor and the steroid bound to it (Iqbal et al.,
1985). Aliquots (0.4ml) of cytosol or nucleosol were
incubated with a constant amount (6,000c.p.m.) of
3H-E2 and increasing amounts of radioinert E2 (0-
18.4pmol). Cytosols were assayed after 2h of
incubation and nucleosols were assayed after 18h
of incubation. In the assay 0.1 ml aliquots of these
incubates were applied to the microassay columns
in duplicate. The column comprises a glass
microcolumn fitted with a cellulose acetate plug,
the upper layer consisting of 0.5ml of Cibacron
Blue 3GA-Sepharose 6B and the lower layer 1 ml of
Sephadex LH-20. The columns were eluted with
either 2.7ml cytosol assay buffer (10mmTris,
1.5mmEDTA, pH 7.4) for the cytosolic ER or
2.7ml nucleosol assay buffer (10mmTris, 250mM
sucrose, 5mM MgCl2, 25mmKCL, pH7.4). After
cutting the columns at the interface of the two gels,
the radioactivity in the Blue gel fraction was
determined. Eleven samples of malignant breast, 9
of normal breast and 3 of endometrium were
assayed.
Competition studiesfor ER
In samples of normal breast (n=9), malignant
breast (n=ll) and endometrium (n=3), cytosolic
and nucleosolic preparations were made as above.
Aliquots (0.4ml) of these were incubated (cytosols
for 2h and nucleosols for 18h) with a constant
amount of 3H-E2 (6,000c.p.m.) and varying
amounts (0-16pmol) of either gestodene or
levonorgestrel, and also using varying amounts (0-
18.4pmol) of radioinert E2. Displacement of the
3H-E2 was studied with the microassay.
Determination ofER employing gestodene as the
binding ligand
The assay for ER, and ER. were carried out on all
samples of malignant, normal and endometrial
tissues exactly as the ER assay described above
except that a constant amount of 3H-gestodene
(6,500c.p.m.) and varying amounts (0-16pmol) of
radioinert gestodene were employed as the binding
ligands. To prevent artefactual measurement of
other receptors, large excesses (100 xfold) of
radioinert DHT, progesterone and cortisol were
included in the incubates to saturate androgen
receptor, progesterone receptor and glucocortico-
steroid receptor respectively.
Protein concentrations were measured using the
BCA protein assay system obtained from Pierce
UK Ltd. employing human serum albumin as
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Competition studies in circulation
(i) Displacement from sex hormone binding globulin
(SHBG) Pooled late pregnancy serum representing
an SHBG value of 250nmol DHT bound I-1 was
diluted 1:20 in buffer (0.05 MTris, 0.005 MCaC12,
pH7.5) and was used throughout. Aliquots (0.4ml)
of the above dilution were incubated as described
for the two-tier column SHBG assay (Iqbal &
Johnson, 1977) with constant amounts
(25,000c.p.m.) of either 3H-DHT, 3H-testosterone,
3H-E2, 3H-5a-androstane-3a(or 3ft,17#-diol and
varying amounts (0-180pmol) of their respective
radioinert moieties. In a parallel series of
experiments displacement of the above tritiated
steroids was carried out with 0-165pmol amounts
of either radioinert gestodene or radioinert
levonorgestrel.
(ii) Displacement from corticosteroid binding globulin
(CBG) The two-tier columns were prepared as
above except that the Sephadex LH-20 gel in the
lower tier was replaced by 1 ml of Sephadex G-25.
The rest of the experimental conditions were as in
(i) above. Displacement of 3H-progesterone and
3H-cortisol was studied by using varying
concentrations (0-180pmol) of their respective
radioinert ligands and in a parallel series of
experiments.displacement of 3H-progesterone and
3H-cortisol was studied by using varying amounts
of radioinert gestodene or levonorgestrel (0-
165pmol).
Results
Of the 11 samples of the carcinoma of the breast
assayed 9 were ER, positive (1-6, 8, 10 and 11,
Table I) and 8 were ERC and ER. positive (1-3, 5,
8, 10 and 11) employing E2 as the binding ligand
(Table I, Figure 1). In normal breast obtained from
the corresponding carcinoma of the breast tissue
(1-6, Table I) ERC was positive in samples 1, 3-6
(Table II); ERC in samples 7-9 was also positive
(Table II, Figure 2). ERn in normal breast was
detected only in two samples (3 and 8, Table II).
All three samples of endometrium were ERC and
ER, positive, ERc: 191, 495, 326fmol E2 bound
mg-1 soluble protein and ERn: 34, 176 and
59fmolmg-1 soluble protein respectively (Kd7.1,
6.8 and 7.2x 10-9molI-1 for ERc, and for ERn
3.0, 3.5 and 4.6 x 10-9mol 1- I respectively).
Competition studies showed that gestodene
displaced 3H-E2 from ER, and ER, in malignant
Table I Oestrogenreceptorincytosol(ERr)andnucleosol(ER,)assayedincarcinoma ofthe
breast tissue using oestradiol (E2) and gestodene as ligands respectively. Kd x 10-9 unless
otherwise stated
ERc ERn ERC ERn
fmol E2 bound mg 1 fmolgestodene bound mg-
Sample no. soluble protein soluble protein
1 505 186 1134 Not measured
(Kd 7.7) (Kd 3.2) (Kd 8.0)
2 21 500 12 531
(Kd 1.8) (Kd 2.1) (Kd 1.0) (Kd 1.6)
3 1102 526 484 526
(Kd 3.1 x 10-8) (Kd 1.4x 10-8) (Kd 8.1) (Kd 1.1 x 10-8)
4 625 Negative 625 Negative
(Kd 8.9) (Kd 5.5)
5 195 13 109 17
(Kd 4.8) (Kd 1.7) (Kd 3.8) (Kd 1.6)
6 45 Negative 79 Negative
(Kd 3.7) (Kd 3.8)
7 Negative Negative Negative Negative
8 106 49 126 57
(Kd 3.1) (Kd 3.6) (Kd 3.4) (Kd 4.4)
9 Negative Negative Negative Negative
10 23 192 36 216
(Kd 2.7) (Kd 2.2) (Kd 2.0) (Kd 1.9)
11 111 52 93 39
(Kd 2.1) (Kd 3.2) (Kd 1.8) (Kd 1.0)450 M.J. IQBAL et al.
Table II Oestrogen receptorincytosol(ERJ) andnucleosol
(ER.) assayed in normal breast tissue. Kd x 1O-9molI-
unless otherwise stated
ERC ERn
fmol oestradiol bound mg-
Sample No. solubleprotein
1 640 Negative
(Kd 1.3 x 10-10)
2 Negative Negative
3 233 87
(Kd 1.5) (Kd 1.4)
4 322 Negative
(Kd 1.5)
5 166 Negative
(Kd 8.8 x 10-10)
6 63 Negative
(Kd 3.2)
7 43 Negative
(Kd 3.2)
8 33 8
(Kd 3.5) (Kd 3.1)
9 105 Negative
(Kd 2.6)
breast tissue samples by a factor 3 times greater
than the natural ligand (Figure 3), 50%
displacement of E2 being caused by 7 xlO-4nmol
E2 added as compared to 2.2 x 10-4nmol gestodene
added. No displacement of 3H-E2 was observed by
gestodene in any sample of normal breast nor the 3
samples of endometrium either from ER, or ER,.
Levonorgestrel showed no displacement of 3H-E2
from ERC or ER, obtained from any sample of
either malignant or normal breast (Figures 1 and 2)
or endometrial tissue.
When the other receptors had been saturated
with excess of their natural ligands ER measured
by gestodene showed values comparable to those
obtained when the natural ligand had been
employed (Table I) with approximately similar Kd
values. ERC or ERn observed to be negative using
E2 as the ligand were also found to be negative
using gestodene as the ligand (Table I). Linear
regression analysis carried out between ERc
measured with E2 and ERC measured with
gestodene gave an r value of +0.6901 (not
significant). Similar analysis for ERn gave an r
value of +0.9987 (P<0.01).
Fifty percent displacement of 3H-DHT, 3H-
testosterone, 3H-E2, 3H-5a-androstane-3a, 17f-diol
and 3H-5a-androstane-3p,17f,-diol from SHBG in
circulation by gestodene were achieved by
concentrations 560%, 235%, 65%, 75% and 80%
0.31
0.2 [
mIu
0.1
0.5 1.0 1.5
Total bound (10-9 M)
b
0.10
COlu 0.06!
0.02
0.1 0.2 0.3
Total bound (10-9 M)
Figure 1 Scatchard plots of binding of oestradiol
0 0, gestodene A /A, and levonorgestrel
x x in (a) cytosol, and (b) nucleosol of
carcinoma of the breast tissue.
of their natural ligand respectively. Similar studies
with levonorgestrel showed that gestodene was
-20% more effective in these displacements than
was the former analogue. No displacement of 3H-
progesterone or 3H-cortisol from CBG in
circulation was caused by either gestodene or
levonorgestrel.OESTROGEN RECEPTORS IN NORMAL AND MALIGNANT BREAST 451
0.15 a Discussion
Gestodene is structurally closely related to levonor-
gestrel and its optical isomer d-norgestrel. The
0.10 latter compound has been shown to displace sex-
steroids from SHBG in circulation (Victor et al.,
m 1u 1976). While it is surprising that a progestogen
£ \t, should not displace progesterone from CBG in 0.05 n A x * \ X serum, the displacement of sex-steroids from SHBG
may be related to the close structural similarities of
the above compounds which all possess a hydroxyl
group in the 17# position of the D ring on the
0.5 1.0 1 5 2.0 steroid molecule (Figure 4). The clinical
Total bound (10-9 M) implications of this displacement of sex steroids in
0.4 b circulation area change in the balance of free sex-
04 steroids and have been discussed by the above
authors.
0.3
mlu 0.2 -
£ ~~~~~~~~~~~OH
0.1
10 X X < v Oestradiol
0.1 0.2 0.3 0.4 0.5 HO
Total bound (10-9 M) CH3
Figure 2 Scatchard plots of binding of oestradiol
0 0, gestodene A /A, and levonorgestrel C-0
x x in (a) cytosol, and (b) nucleosol of normal
breast tissue.
Progesterone
100 0
OH3
80 JOH
H2C
E ;----- C-CH
C)
60 5 0 50Gestodene
U,
4_0 t H3
IOH
H2 C
20 -----C -CH
05 10 510 1~~~~~~~~~ 5~~~ Levonorgestrel
Steroid added (Mx 10-12) Figure4 Structures of oestra, 1,3,5(10)-triene-3,17f,-
Figure 3 Semi-logarithmic plot of % displacement of diol (oestradiol), pregn-4-ene-3,20-dione (progesterone),
3H-oestradiol by radioinert oestradiol 0 O, and 17a-ethinyl-13,B-ethyl-17,B-hydroxy-4,15-gonadiene-3-
gestodene x- x in malignant breast cytosols. one (gestodene), and L-13-ethyl-17a-ethinyl-17f,-
Mean +s.d. of 7 determinations. hydroxy-gonen-3-one (levonorgestrel).
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In relation to the binding of gestodene to ER in
malignant breast tissue, the findings are much more
unexpected and have far reaching implications. This
study demonstrates for the first time that a
steroidal compound exhibits binding to ER from
malignant breast but not to that from normal
breast. This indicates a structural difference
between the two receptors. In competition studies
the results show that gestodene can displace 3H-E2
by about 3-fold as compared to the natural ligand,
however, when ER from malignant breast tissue is
measured using this synthetic steroid there is little
difference in the total steroid bound or in the
dissociation constant suggesting that gestodene
prevents binding of E2 not only by competing for
the binding site on ER but perhaps also by
interfering with the formation of E2-ER complex.
The high positive correlation between ERn
measured with E2 and that measured with
gestodene supports this hypothesis.
The evidence presented here suggests that the
binding site and therefore the structure of ER
extracted from malignant breast is different from
that in either normal breast of endometrium and
that gestodene may be of clinical value as an
antioestrogen in the management of malignant
breast disease.
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